Caris Life Sciences has entered into a new senior secured financing agreement totaling up to $1.2 billion with funds managed by Blue Owl Capital and Blackstone. The structure includes an initial term loan of $400 million funded at closing, a committed delayed‑draw term facility of up to $300 million, and an uncommitted incremental facility of up to $500 million. Read More

Visit SFNet's Deal Table